Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

We are a large multi-disciplinary department, which aims to tackle some of the world’s biggest health challenges by integrating innovative basic biology with cutting edge clinical research. We have internationally renowned programmes in a range of areas including cardiovascular sciences, diabetes and endocrinology, immunology, haematology and pathology. Find out more about what we do. 

What's new

Enterprise Associate Interview with Dr Shilpa Nagarajan

Dr Shilpa Nagarajan is one of the MPLS Enterprise and Innovation Fellows for 2022-23.

Group of men and women wearing gene-themed t-shirts in front of a gazebo saying The Gene Therapists.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

More news

COVID-19 research

Photo composite showing a comparison of Peri-imap pvat images at baseline, and after covid infection. The delineation in the covid image is much less clear.

Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies

RDM researchers tested the method in COVID-19 patients, to find that the results predicted in-hospital mortality.

Structural model of the mosaic-8 RBD-mi3 nanoparticle design. Fan et al., (in press) https://www.biorxiv.org/content/10.1101/2022.06.28.497989v1 Cohen et al., (2022) Science https://www.science.org/doi/10.1126/science.abq0839

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

More research